Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) announces that it has been selected for inclusion in the Dow Jones Sustainability World Index (DJSI World), a leading global index of ESG investment, for the third consecutive year.
We are happy to announce the launch of the dedicated calibrators and controls for Edoxaban which are to be used with Biophen DiXal and Biophen Heparin (LRT). With this new addition, we now have a complete portfolio for direct oral anticoagulants (DOACs) measurement.
Sysmex Corporation has established a new subsidiary in Egypt and will begin conducting direct sales and services with the aim of expanding its business in the Middle East.
Sysmex Corporation, the Foundation for Biomedical Research and Innovation at Kobe and Kyoto University have begun joint research related to the Drug Discovery Innovation Program: Developing Technologies for Diagnosing Immunological Diseases, which the Foundation is promoting. Through joint research, the three organizations aim to create a diagnostic system that will enable the early detection of autoimmune disease and chronic inflammatory disease.
Labtests, a division of Healthscope NZ, is one of the largest private pathology providers in New Zealand and have become the first laboratory in the country to install and begin processing specimens with Sysmex’s innovative UN-Series. Urinalysis testing is commonly requested by GPs to screen for urinary tract infections, kidney disorders, and liver problems. Labtests routinely receive 1,300 specimens each day from the Auckland and Northland regions to test for urinary tract infections alone.
Sysmex Corporation responded to a call by the Japan International Cooperation Agency (JICA) for proposals under the second fiscal 2017 Collaboration Program with the Private Sector for Disseminating Japanese Technology for Social and Economic Development of Developing Countries. Sysmex’s proposal “Dissemination of Automated Urinalysis Diagnosis technology in the Republic of Ghana” was selected.
Sysmex Corporation announces its accreditation under the international standard ISO Guide 34 (General requirements for the competence of reference material producers). It is important for laboratories to ensure traceability, in order to ensure the quality of their test results. Laboratories ensure traceability through routine calibration and quality control. The standard materials used in this calibration […]
Sysmex Corporation offers a new network solution, Caresphere,™ to provide new value through the intelligent use of information by people involved in testing and healthcare, with a view to accelerating the future use of information in healthcare. Caresphere™ creates an environment for linking and analyzing a variety of information from testing instruments and laboratory information […]
“Although it coincides with an even bigger anniversary, Sysmex Corporation celebrating its 50th birthday, we want to pay special attention to our two decades of commitment to the Asia Pacific region,” remarked Frank Buescher, President & CEO of Sysmex APAC.
Sysmex Corporation celebrated the 50th anniversary of its establishment on February 20, 2018. We offer our heartfelt appreciation for the support of our customers and all other stakeholders since the time of our establishment in 1968.
Hamburg, Germany, 2018.01.16 – Sysmex Inostics, a global leader in blood based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology, today announces data from an abstract of a study comparing the performance of plasma RAS mutation detection by two commercial liquid biopsy testing platforms, OncoBEAM RAS CRC and Idylla ctKRAS Mutation Test. The […]
Sysmex Asia Pacific Pte Ltd, a subsidiary of Sysmex Corporation signed a distribution agreement with genedrive plc the near patient molecular diagnostics company, for its CE-marked Genedrive® HCV ID Kit and Genedrive® platform in the Asia Pacific region. This is genedrive’s second agreement signed with a subsidiary of Sysmex Corporation, a world leader in clinical […]